sorafenib (BAY 43-9006)

inhibits tumor cell proliferation and angiogenesis by targeting RAF KINASES and VEGF RECEPTORS; multikinase inhibitor that targets serine/threonine and receptor tyrosine kinases to decrease tumor growth and angiogenesis; FDA approved orphan drug indication for hepatocellular carcinoma in 2006

Also Known As:

Networked: 2977 relevant articles (468 outcomes, 862 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Escudier, Bernard: 31 articles (08/2015 - 05/2006)
2.	Cheng, Ann-Lii: 29 articles (10/2015 - 01/2009)
3.	Kudo, Masatoshi: 29 articles (10/2015 - 06/2010)
4.	Flaherty, Keith T: 26 articles (09/2015 - 03/2006)
5.	Porta, Camillo: 25 articles (08/2015 - 07/2008)
6.	Dent, Paul: 24 articles (10/2015 - 10/2005)
7.	Santoro, Armando: 23 articles (03/2015 - 09/2006)
8.	Wright, John J: 22 articles (09/2015 - 08/2007)
9.	Rini, Brian I: 22 articles (08/2015 - 03/2006)
10.	Goldwasser, François: 20 articles (01/2015 - 01/2010)

Related Diseases

1.	Hepatocellular Carcinoma (Hepatoma) 07/01/2013 - "The aim of this study was to evaluate the efficacy of sorafenib, compared to best supportive care (BSC), in two cohorts of patients which presented with hepatocellular carcinoma (HCC) recurrence after LT. " 01/01/2014 - "An open-label, single arm, investigator-initiated Phase II study (NCT0071279) was conducted at four Asia-Pacific centers to evaluate the safety and efficacy of sequential radioembolization-sorafenib in patients with hepatocellular carcinoma (HCC) not amenable to curative therapies. " 01/01/2012 - "No systemic therapy had been proven effective in patients with advanced hepatocellular carcinoma (HCC) until 2007, when a large randomized trial with sorafenib demonstrated a clinically relevant prolongation of survival. " 09/15/2015 - "To assess the efficacy of continued administration of sorafenib for patients with unresectable hepatocellular carcinoma (HCC) treated with local regional therapy (LRT) after a complete response (CR), also, the adverse events of sorafenib after discontinuation of administration were observed. " 09/01/2015 - "Sustained complete remission of advanced hepatocellular carcinoma with sorafenib therapy."
2.	Neoplasms (Cancer) 09/18/2015 - "Careful patient selection and a tailored treatment modality for every patient, either potentially curative (surgical treatment and tumor ablation) or palliative (transarterial therapy, radioembolization and medical treatment, i.e., sorafenib) is mandatory to achieve the best treatment outcome. " 01/01/2015 - "Besides, long-term sorafenib administration is safe, and patients should continually receive sorafenib to avoid recurrence after complete remission of cancer. " 07/01/2013 - "Patients with epithelial OC or primary peritoneal cancer in complete remission were randomized to sorafenib 400mg BID or matching placebo. " 07/01/2015 - "In vivo administration of sorafenib resulted in the significant growth inhibition of ACHN/sh-Akt1 tumor compared with that of ACHN/C tumor, and despite the lack of Ki-67 labeling index between ACHN/sh-Akt1 and ACHN/C tumors, apoptotic index in ACHN/sh-Akt1 tumor in mice treated with sorafenib was significantly greater than that in ACHN/C tumor. " 02/01/2015 - "In vivo, sorafenib treatment only led to a moderate tumor growth inhibition, although significant reduction of vascularization and tumor growth kinetics was observed. "
3.	Renal Cell Carcinoma (Grawitz Tumor) 11/01/2011 - "Sorafenib was effective in Japanese patients with advanced renal cell carcinoma in general clinical practice and was tolerated although most patients required dose reduction or interruption of therapy. " 02/01/2013 - "Sorafenib has proven efficacy in metastatic renal cell carcinoma (mRCC). " 08/01/2008 - "Sorafenib is an oral multikinase inhibitor that has been proven effective as a single-agent therapy in renal cell carcinoma, and there is a strong rationale for investigating its use in combination with other agents. " 06/01/2007 - "These findings are consistent with other clinical results from this trial of advanced renal cell carcinoma patients treated with sorafenib, which included significantly greater progression-free survival and low risk for treatment limited toxicities." 01/01/2011 - "High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma."
4.	Neoplasm Metastasis (Metastasis) 09/01/2013 - "Sorafenib is a molecularly targeted agent that has been proven effective for treating advanced HCC with extrahepatic metastasis. " 12/01/2009 - "Sorafenib was significantly less effective in patients with bone metastases. " 05/01/2012 - "Although a lung CT scan done 2 months after initiation of sorafenib suggested stability of the disease, MRI studies done at 3 and 6 months showed clear progression with an increase in the size of the lung and pancreatic metastases. " 09/01/2007 - "Results of a sub-evalution of a randomized phase III trial show that sorafenib offers encouraging activity in the treatment of patients with RCC and brain metastases. " 10/01/2015 - "Sorafenib treatment may be a bridge to curative resection in selected patients with initially unresectable advanced HCC, even in cases involving multiple extrahepatic metastases. "
5.	Thyroid Neoplasms (Thyroid Cancer) 05/01/2014 - "Sorafenib has proven efficacy in advanced differentiated thyroid cancer (DTC), but many patients must reduce the dose or discontinue treatment because of toxicity. " 01/01/2015 - "In this study we aim to better characterize molecular effects and efficacy of sorafenib against thyroid carcinoma cells with various histological origins and different BRAF mutational status. " 03/01/2011 - "To investigate the efficacy of sorafenib in progressive metastatic Medullary Thyroid Carcinoma (MTC), for which there is currently no effective treatment. " 11/01/2014 - "Efficacy of sorafenib and impact on cardiac function in patients with thyroid cancer: a retrospective analysis." 02/01/2014 - "To investigate the efficacy of sorafenib in progressive radioiodine resistant metastatic thyroid carcinoma. "

Related Drugs and Biologics

1.	sunitinib (Sutent)
2.	Protein-Tyrosine Kinases (Tyrosine Kinase)
3.	Phosphotransferases (Kinase)
4.	bevacizumab
5.	everolimus
6.	temsirolimus
7.	Sirolimus (Rapamycin)
8.	sorafenib (BAY 43-9006)
9.	gemcitabine
10.	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Liver Transplantation
3.	Heterologous Transplantation (Xenotransplantation)
4.	Immunotherapy
5.	Transplants (Transplant)